Phase IIT Trial of SNA014

Clinical Study of 68GA-labeled Claudin 18.2 Developer Combined with PET/CT for Imaging of Gastric or Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for gastric or gastroesophageal junction

Inclusion Criteria:

• Age range of 18 to 75 years old (including boundary values);
• Individuals with behavioral capacity who voluntarily participate in this clinical study and sign an informed consent form (ICF);
• Diagnosed G/GEJ adenocarcinoma and pancreatic cancer;
• Gastroscopy/CT/MRI/PET-CT examination results within the past month (if any);
• Pathological test results and Claudin18.2 immunohistochemistry results within the past year (if available).

Exclusion Criteria:

• Merge patients with other clearly diagnosed malignant tumors:
• Uncontrolled severe infections or individuals with other serious illnesses;
• Those with an expected survival period of less than or equal to three months;
• Pregnant or lactating patients, as well as reproductive age patients who refuse to take appropriate contraceptive measures during this trial;
• investigators determine that patients who are not suitable to participate in this study;